An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Completed · Phase 3

Conditions studied: Thyroid Cancer

In brief

The purpose of this study is to learn how hereditary or sporadic medullary thyroid cancer patients, treated with ZD6474, react to the drug, what happens to ZD6474 in the human body, about the side effects of ZD6474, and if ZD6474 can decrease or prevent the growth of tumors.

Key facts

Study ID

NCT00410761

Run by

Genzyme, a Sanofi Company

People needed

331

Starts

2006-11-23

Expected to finish

2024-07-26

Last updated by the study team

2025-09-24

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed diagnosis of unresectable, locally advanced or metastatic hereditary or sporadic Medullary Thyroid Cancer.
• Presence of measurable tumor
• Able to swallow medication

You may not qualify if…

• Major surgery within 4 weeks before randomization
• Last dose of prior chemotherapy received less than 4 weeks prior to randomization
• Radiation therapy within the last 4 weeks prior to randomization(with exception of palliative radiotherapy)
• Brain metastases or spinal cord compression, unless treated at least 4 weeks before first dose and stable without steroid treatment for 10 days
• Significant cardiac events
• Previous ZD6474 treatment

Where it is running

• University Arkansas Site Number : 3 — Little Rock, Arkansas, United States
• Investigational Site Number 8 — San Francisco, California, United States
• USCF / Mt Zion Medical Center Site Number : 8 — San Francisco, California, United States
• Investigational Site Number 9 — Aurora, Colorado, United States
• University Of Colorado Health Sciences Center Site Number : 9 — Aurora, Colorado, United States
• Investigational Site Number 11 — New Haven, Connecticut, United States
• Yale University School Medicine Site Number : 11 — New Haven, Connecticut, United States
• Investigational Site Number 15 — Jacksonville, Florida, United States
• Mayo Clinic- Site Number : 15 — Jacksonville, Florida, United States
• Investigational Site Number 18 — Chicago, Illinois, United States
• The University Of Chicago Site Number : 18 — Chicago, Illinois, United States
• Investigational Site Number 17 — Lexington, Kentucky, United States
• The University Of Kentucky Site Number : 17 — Lexington, Kentucky, United States
• Dana Farber Cancer Institute Site Number : 2 — Boston, Massachusetts, United States
• Investigational Site Number 2 — Boston, Massachusetts, United States
• Investigational Site Number 7 — Detroit, Michigan, United States
• Wayne State University / Harper Hospital Site Number : 7 — Detroit, Michigan, United States
• Investigational Site Number 14 — Rochester, Minnesota, United States
• Mayo Clinic- Site Number : 14 — Rochester, Minnesota, United States
• Investigational Site Number 10 — St Louis, Missouri, United States
• Washington University School Of Med Site Number : 10 — St Louis, Missouri, United States
• Investigational Site Number 6 — Cincinnati, Ohio, United States
• University Of Cincinnati Site Number : 6 — Cincinnati, Ohio, United States
• Investigational Site Number 22 — Portland, Oregon, United States
• Investigational Site Number 3 — Little Rock, Arkansas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.